Liší se mezi sebou v účinnosti antipsychotika druhé generace v léčbě onemocnění schizofrenního okruhu?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F07%3A00000339" target="_blank" >RIV/00216208:11120/07:00000339 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023752:_____/07:00000671

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?

Popis výsledku v původním jazyce

Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Results. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine)show comparable efficacy. Conclusion. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.

Název v anglickém jazyce

Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?

Popis výsledku anglicky

Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Results. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine)show comparable efficacy. Conclusion. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

<a href="/cs/project/1M0517" target="_blank" >1M0517: Centrum neuropsychiatrických studií 2005-2009 (Neurobiologie v klinické aplikaci)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Clinical Psychiatry

ISSN

1040-1237

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

133-143

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—